MONTREAL, CANADA: Sunshine Biopharma Inc, a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, announced an agreement with Lonza, a leading development and manufacturing company, for the manufacture of its anti-cancer drug, Adva-27a.
Lonza’s expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients, was an ideal fit for Sunshine’s Adva-27a. Lonza’s manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and tonne quantities for commercialization. Manufacturing will begin at Lonza’s Nansha, China facility with the remaining key steps to be conducted in Lonza’s high containment cytotoxic facility in Visp, Switzerland.
“We are delighted to have a global leader like Lonza as our manufacturing partner. We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing and recent fund raising efforts,” said Dr Steve N Slilaty, President and CEO, Sunshine Biopharma.
© Worldofchemicals News